Furthermore, Buch et al. [198] found that fast acetylators (NAT2*4) are more frequent in oral cancer patients (53.7%) than in controls (43.9%; OR = 1.55; 95%CI = 1.08–2.20; P = 0.03). This evidence concerns the gene NAT2 and lip and oral cavity carcinoma.